Praxis Precision Medicines to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors [Yahoo! Finance]